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PURPOSE. We previously identified an oxysterol, VP1-001 (also known as compound 29), that
partially restores the transparency of lenses with cataracts. To understand the mechanism of
VP1-001, we tested the ability of its enantiomer, ent-VP1-001, to bind and stabilize aB-
crystallin (cryAB) in vitro and to produce a similar therapeutic effect in cryAB(R120G) mutant
and aged wild-type mice with cataracts. VP1-001 and ent-VP1-001 have identical
physicochemical properties. These experiments are designed to critically evaluate whether
stereoselective binding to cryAB is required for activity.
METHODS. We compared the binding of VP1-001 and ent-VP1-001 to cryAB using in silico
docking, differential scanning fluorimetry (DSF), and microscale thermophoresis (MST).
Compounds were delivered by six topical administrations to mouse eyes over 2 weeks, and
the effects on cataracts and lens refractive measures in vivo were examined. Additionally, lens
epithelial and fiber cell morphologies were assessed via transmission electron microscopy.
RESULTS. Docking studies suggested greater binding of VP1-001 into a deep groove in the
cryAB dimer compared with ent-VP1-001. Consistent with this prediction, DSF and MST
experiments showed that VP1-001 bound cryAB, whereas ent-VP1-001 did not. Accordingly,
topical treatment of lenses with ent-VP1-001 had no effect, whereas VP1-001 produced a
statistically significant improvement in lens clarity and favorable changes in lens morphology.
CONCLUSIONS. The ability of VP1-001 to bind native cryAB dimers is important for its ability to
reverse lens opacity in mouse models of cataracts.
Keywords: aB-crystallin, enantiomer, pharmacologic chaperone, biophysical assay, in vivo
cataract model
A densely packed network of crystallin proteins provides theoptical clarity and unique refractive index of lens tissue. In
humans, the lens has limited capacity for new protein
synthesis, requiring crystallins to remain soluble and stable
for decades.1 This remarkable feature is facilitated in part by aB-
crystallin (cryAB), a chaperone that helps to maintain protein
stability and preserve lens transparency.2,3 The active form of
cryAB consists of dimers and larger oligomers4 that prevent
client proteins from aggregating via numerous, promiscuous,
low-affinity amphipathic interactions.5,6
Structural or functional alterations in cryAB or its related
isoform, cryAA, by mutation or posttranslational modification
are associated with aggregation7 and early-onset hereditary
cataracts.8–10 Mutant cryAB(R120G) is prone to aggregation in
vitro11 and is associated with childhood cataracts.12 R120G
disrupts two native salt bridges, which normally contribute to
the dimerization of two cryAB protomers across an antiparallel
b-sheet interface.13 Repeating units of cryAB dimers typically
assemble into larger oligomers, but R120G disrupts overall
assembly and function of the chaperone. We previously showed
that the lenses of cryAB(R120G) knock-in mice contain a
greater proportion of insoluble, aggregated cryAB and develop
opacities at an early age as compared with wild-type (WT)
mice.14 In addition, cryAB(R120G) oligomers in solution had a
2- to 3-fold higher average molecular mass than WT cryAB.
Similar to cryAB(R120G), cryAA(R49C) knock-in mice develop
lens opacity at an early age and exhibit a smaller proportion of
water-soluble cryAA as compared with WT mice.8 Importantly,
these mutations appear to damage the chaperone functions of
crystallins. Interactions with client proteins, such as vimentin,
are increased for cryAB(R120G) compared with WT in
epithelial and fiber cells of mouse lenses.14 Along with aging
and trauma to the lens, cryAB(R120G) can cause aggregate
formation that leads to lens opacification and cataract
formation.15,16 Recent studies identified sterols as pharmaco-
logic chaperones that reverse crystallin aggregation in cata-
racts.17–19 Thus, one potential therapeutic approach for
hereditary and/or age-associated cataracts is to bind and
stabilize the native cryAB dimer.
We previously identified VP1-001, an oxysterol that limits
cryAB aggregation in a thermal shift assay and restores
transparency to the lenses of cryAB(R120G) heterozygous
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mice.17 We hypothesized that VP1-001 acts as a small-molecule
pharmacologic chaperone20 by binding to a site within cryAB
that stabilizes its native conformation. Indeed, nuclear mag-
netic resonance (NMR) studies suggested that a cryptic binding
site for VP1-001 is located in a deep groove in the cryAB dimer.
However, this compound may also act as a chemical
chaperone, similar to glycerol or trimethylamine-N-oxide, to
nonselectively protect cryAB from misfolding. In contrast to
pharmacologic chaperones, chemical chaperones do not
interact with a discrete binding site. A third possibility is that
VP1-001 may partition into the lipid bilayers of lens cells,
exerting its effect by influencing membrane fluidity. Further
development of this therapeutic strategy requires clearer
understanding of the mechanisms of action of VP1-001.
We measured binding of VP1-001 and its enantiomer, ent-
VP1-001, to cryAB. Despite having physicochemical properties
identical to VP1-001, the enantiomer does not engage the
chiral cryAB pocket. Thus, ent-VP1-001 was a useful tool for
determining whether these compounds act through binding
cryAB or through an alternative mechanism. Indeed, only VP1-
001 restored lens transparency in mouse models of hereditary
and age-associated cataracts. These results strongly support
selective binding of VP1-001 to cryAB with subsequent
stabilization of the native cryAB conformation and partial
restoration of crystallin networks. These findings clarify the
mechanism of action of VP1-001 and support optimization of
affinity for cryAB in the development of potential cataract
treatments.
METHODS
Docking
Crystallographic (Protein Data Bank [PDB] code: 2WJ721) and
closed models of cryAB (receptor) were created using a
standard docking protocol to prepare hot spots (spheres) and
scoring grids (van der Waals, electrostatics, and ligand
desolvation) as previously described,22 with one modification:
qnifft23 was used in place of Delphi to prepare the electrostatic
scoring grids. qnifft allows for the same calculation of Poisson-
Bolzmann finite difference electrostatics but is available as an
open-source software package.
Modeling was performed using UCSF (University of
California, San Francisco, CA, USA) DOCK 3.624,25 as licensed
by Blue Dolphin (San Francisco, CA, USA). The initial criteria
for the model were a good overall fit of the ligand to receptor,
favorable hydrophobic and polar complementarity, and mini-
mal unfavorable interactions.26 To obtain closed receptor
models, the crystallographic structure was modified as follows.
In Chimera,27 one monomer was rotated toward the other
along an axis determined by the centroids of the H-bonding
atoms of the beta sheet through which the monomers were
joined. In this approach, the promoters were considered rigid
bodies. We created models in 48 increments, from 48 to 208. In
all cases, the hydroxyl of the ligand was constrained to engage
both arginines (R120) at either end of the dimer interface.
Synthesis of ent-VP1-001
Compound synthesis was adapted from a previously described
procedure.28 The full synthetic route can be found in
Supplementary Figure S1, and the characterization of each
intermediate is described in the Supplementary Methods.
Protein Purification
Three recombinant proteins were expressed and purified from
Escherichia coli BL21(DE3) cells (Invitrogen, Thermo Fisher
Scientific, Invitrogen, Waltham, MA, USA): a cryAB core
domain, a-crystallin domain (ACD) mutant, WT ACD, and full-
length cryAB(R120G). For the ACD mutant, the mutation E87C
was induced by a mutagenesis kit (QuikChange; Agilent
Technologies, Santa Clara, CA, USA) (forward primer: GGA
TGT GAA GCA CTT TAG CCC GTG CGA ACT GAA AGT TAA
GGT TCT GG; reverse primer: CCA GAA CCT TAA CTT TCA
GTT CGC ACG GGC TAA AGT GCT TCA CAT CC), and the
protein was expressed and purified as previously described.29
The WT ACD (amino acids 68–153) with an N-terminal
hexahistidine (His6) tag followed by a tobacco etch virus
(TEV) protease cleavage site was purified from E. coli
expressing a pET28a plasmid (GenScript, Piscataway, NJ,
USA) harboring the construct. The full-length cryAB(R120G)
with an N-terminal His6 tag was purified from E. coli
expressing a pD441 plasmid (ATUM) harboring the construct.
Cultures were induced at an optical density of 3.0 by adding 1
mM isopropyl-b-D-thiogalactopyranoside to rich media (Terrific
Broth; Thermo Fisher Scientific, Pittsburgh, PA, USA) and
incubated at 258C for 18 hours with agitation at 200 RPM.
Pellets were centrifuged for 10 minutes at 7000g and flash
frozen at 808C for long-term storage. Frozen pellets were
thawed and resuspended in 100 to 150 mL of lysis buffer (50
mM Tris, pH 8.0; 150 mM NaCl; 10 mM imidazole; 5% glycerol)
or in lysis buffer containing 6 M urea and 0.5 mM [tris(2-
carboxyethyl)phosphine] (TCEP) (for full-length cryAB) and
homogenized by an homogenizing valve (EmulsiFlex-C3;
Avestin, Inc., Ottowa, ON, Canada) with a target pressure of
1500 psi). The homogenates were clarified by centrifuging for
15 minutes at 46,000g. The supernatants were agitated with 15
mL Ni-NTA resin at 48C for 2 hours. WT ACD or full-length
cryAB(R120G) bound to resin was collected and washed on a
glass filter with 150 mL of lysis buffer or lysis buffer with urea
and TCEP, respectively, and then with 100 mL wash buffer or
urea wash buffer (lysis buffers with 30 mM imidazole). Proteins
were eluted in five 15-mL fractions with elution buffer or urea
elution buffer (lysis buffers with 400 mM imidazole) or until
eluants were colorless. The eluant containing WT ACD was
agitated overnight at 48C with TEV protease (purified in-
house30 from ATCC plasmid pRK793 in E. coli BL21
CodonPlus(DE3)-RIL cells) to remove the His6 tag. The protein
was centrifuged for 10 minutes at 4000g. The supernatant was
concentrated to 5 mL and refolded, and buffer exchange was
performed via size-exclusion chromatography (SEC) with SEC
buffer (13 PBS [pH 7.5], 5% glycerol). The eluants containing
full-length cryAB(R120G) were combined and concentrated to
5 mL and then quickly diluted in 95 mL 0.13 PBS with rapid
stirring. The refolded protein was centrifuged for 10 minutes at
4000g, and the supernatant was dialyzed overnight into 4 L
0.13 PBS. All proteins were flash frozen and stored at 808C.
Full-length proteins were thawed and centrifuged at 10,000g
for 3 minutes prior to plating assays.
Differential Scanning Fluorimetry (DSF)
DSF was performed on recombinant ACD in the presence of
either the vehicle control (4% ethanol) or increasing concen-
trations of compounds in 4% ethanol. A sample of 2.4 lL of the
compound stocks were thoroughly mixed with 51.6 lL of 70
lM recombinant cryAB ACD protein in DSF buffer (50 mM Tris-
HCl [Invitrogen], 100 mM NaCl, 0.5 mM ZnCl2, 0.5 mM MgCl2,
0.5 mM CaCl2, pH 8.0) and 6 lL 1003 orange protein gel stain
(SYPRO; Invitrogen; 50003 stock. DSF buffer is diluent for
intermediate stock). Then, 10 lL was added in quadruplicates
to a 384-well reaction plate (MicroAmp Optical; Thermo Fisher
Scientific, Applied Biosystems, Waltham, MA, USA). The plate
was sealed with a MicroAmp Optical adhesive film (Applied
Biosystems), centrifuged at 1,000g for 2 minutes, and loaded
Enantiomeric Study of VP1-001 Mechanism of Action IOVS j August 2019 j Vol. 60 j No. 10 j 3321
Downloaded from iovs.arvojournals.org on 08/06/2019
into a real-time PCR system (QuantStudio 6 Flex; Applied
Biosystems). The DSF assay was performed by heating the plate
from 308C to 808C with 0.58C increments per cycle over 100
cycles. Each cycle consisted of a 90-second hold at the desired
temperature and a 20-second hold at 258C, during which the
fluorescent signal (520 nm excitation/558 nm emission) was
measured.
The DSF data was fitted using a Boltzmann model (Prism,
version 7; GraphPad Software, San Diego, CA, USA) using a
fitting range from 258C to 38 to 58C above the temperature at
which the fluorescence signal was highest. The melting
temperature (Tm) was determined to be the temperature at
the midpoint between the highest and lowest fluorescent
signals on the curve.
Microscale Thermophoresis (MST)
MST was performed on a mixture containing 10 lM full-length
cryAB(R120G) and 100 nM of the ACD mutant labeled with a
thiol-reactive dye (Alexa Fluor; Thermo Fisher Scientific,
Invitrogen) 488 C5 maleimide (AF488-ACD). The compounds
were first diluted to 10 mM in dimethylsulfoxide (DMSO) and
then serially diluted 2-fold in DMSO before use. Samples
containing 9 lL of MST-TP buffer (50 mM Tris, 150 mM NaCl,
10 mM MgCl2, 0.05% Tween-20, 0.1% polyethylene glycol-
8000, pH 7.4), 1 lL of compound (VP1-001 or ent-VP1-001),
and 10 lL cryAB mixture (for a final concentration of 5 lM
cryAB in 5% DMSO) were incubated for 15 minutes at room
temperature and then applied to capillaries (MO-K022) loaded
into a single laser microscale thermophoresis instrument
(Monolith NT.115; NanoTemper Technologies GmbH,
Mu¨nchen, Germany) for analysis (80% blue laser power,
medium MST power, standard conditions). The response to
ligand titration was determined at the 1.5-second threshold and
fit to the KD model using NanoTemper analysis software. The
fraction bound for ent-VP1-001 was normalized to VP1-001 due
to the inability to saturate curves with the enantiomer.
Animals and Dosing
All animal procedures adhered to the ARVO Statement for Use
of Animals in Ophthalmic and Vision Research. WT (C57BL/6J)
mice (218–391 days old) and heterozygous cryAB(R120G)
mice (on a C57BL/6J background; 187–362 days old) were
used in this study. The Mouse Genetics Core at Washington
University (St. Louis, MO, USA) was responsible for care,
breeding, and genotyping of mice. Single nucleotide polymor-
phism services from DartMouse (Dartmouth Geisel School of
Medicine, Lebanon, NY, USA) previously converted these mice
to a C57BL/6J background using speed congenics. This process
utilizes strain-specific polymorphic markers to speed up the
conversion process from a mixed 129Sv/C57BL/6J background
to >98% C57BL/6J background (Supplementary Fig. S2). These
mice do not carry the CP49 mutation; thus, cataracts in these
mice are unlikely to be due to the CP49 mutation present in
the 129Sv strain.31
One eye of each animal was treated topically with either
0.04% ent-VP1-001 or 0.04% VP1-001 (1 mM in 8% cyclodex-
trin), and the other eye was treated with vehicle alone (8%
cyclodextrin) three times per week (Monday, Wednesday, and
Friday) for 2 weeks. Mouse cohorts were age matched between
treatment groups (see Fig. 4).
Slit Lamp Biomicroscopy
Mice were examined by slit lamp biomicroscopy (slit lamp
model BG-2GN, serial number 941752; Topcon, Oakland, NJ,
USA) 3 days following the final dosing. Prior to observation, the
pupils were dilated with a 1% USP tropicamide ophthalmic
solution and 10% USP phenylephrine hydrochloride solution in
a 9:1 ratio. The slit was placed orthogonal to the mouse for
best viewing of the lens opacities. Each eye was recorded on a
video camera in the night mode (DCR-DVD403 3MP DVD
Handycam Camcorder with 103 optical zoom with Carl-Zeiss
Vario-Sonnar Super Steady Shot; Sony, Tokyo, Japan). Still
frames were extracted from the videos using software (Topaz
Moment; free of charge from Topaz Labs, Dallas, TX, USA) or
Adapter (Adapter; Macroplant, McKinney, TX, USA). Improve-
ments in lens transparency were scored using a system we
previously modeled after LOCSIII but adapted for mice.14,17
Specifically, an independent observer who did not apply the
topical treatments scored each eye from 0 to 4 using the
following system: stage 0, clear lens; stage 1, loss of normal
lens appearance in the anterior, posterior, and nuclear regions
of the lens; stage 2, distinct nuclear opacity accompanied by
discrete anterior lens changes; stage 3, increased opacity in
nuclear and cortical regions, discrete punctate opacities, and
overall opacities covering approximately two-thirds of the lens;
stage 4, complete loss of transparency and opacities involving
most of the cortex and nucleus.
Gel Permeation Chromatography (GPC) of Water-
Soluble Lens Crystallins
The treated mouse eyes were enucleated, and the lenses were
excised and placed in individual tubes for analyses. The lenses
were homogenized with disposable grinders (Axygen, Union
City, CA, USA) in 1.5-mL Eppendorf tubes containing 400 lL
PBS and centrifuged for 30 minutes at 48C and 10,286g. The
supernatants were filtered through a 0.22-lm filter, transferred
to a vial, and analyzed by GPC as follows. Proteins (100 lL
aliquots of the supernatants) were separated in succession on
SEC columns (G3000 XL and G5000 XL; Tosoh Bioscience LLC,
Prussia, PA, USA) in line with a TDA302 detector that measured
the refractive index (RI), right-angle light scattering (RALS),
viscosity, and UV absorbance (Malvern PANalytical Products,
Westborough, MA, USA).
Transmission Electron Microscopy of Treated
Lenses
For ultrastructural analyses, the lenses were fixed in 2%
formaldehyde–2.5% glutaraldehyde (Polysciences, Inc., War-
rington, PA, USA) in 100 mM sodium cacodylate buffer (pH 7.2)
for 2 hours at room temperature and then overnight at 48C.
The samples were washed in sodium cacodylate buffer at room
temperature and postfixed in 1% osmium tetroxide (Poly-
sciences, Inc.) for 1 hour. The samples were then rinsed
extensively in deionized water prior to en bloc staining with
1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA, USA)
for 1 hour. Following several rinses in deionized water, the
samples were dehydrated in a graded ethanol series and
embedded in resin (Eponate 12; Ted Pella, Inc.). Sections 95-
nm thick were cut with an ultramicrotome (Leica Ultracut
UCT; Leica Microsystems Inc., Bannockburn, IL, USA), stained
with uranyl acetate and lead citrate, and viewed on a
transmission electron microscope (JEOL 1200 EX; JEOL USA
Inc., Peabody, MA, USA) equipped with an 8-megapixel digital
camera and software (Image Capture Engine V602; Advanced
Microscopy Techniques, Woburn, MA, USA). Multiple images of
the lens epithelial and lens fiber cells were captured in the
equatorial region. Trained staff at the Molecular Microbiology
Imaging Facility at Washington University performed all
processing, plastic embedding, and ultrastructural analysis by
electron microscopy (EM).
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Morphologic damage to the lens epithelium and lens fiber
cells was documented in EM images of the equatorial region of
the lens. Morphologic damage to the lens epithelium included
loss of cell-cell contacts, presence of vacuoles, and loss of
contacts at the epithelial-capsule interface. Morphologic
damage to the lens fiber cells included nonuniform cell size,
irregular packing, and limited membrane blebbing. The
numbers of damaged cells were determined in each image,
and a t test was used to determine statistical significance. EM
analysis of WT, untreated mouse lenses can be found in
Supplementary Figure S3.
RESULTS
VP1-001 is an oxysterol that contains eight chiral centers. To
determine if binding to cryAB is an important aspect of
compound activity, we synthesized the enantiomer, ent-VP1-
001 (Fig. 1A; Supplementary Fig. S1). Importantly, VP1-001 and
ent-VP1-001 have identical physicochemical properties (e.g.,
molecular mass and calculated logP) but mirror-image three-
dimensional configurations (Fig. 1B). Thus, we predicted that
only VP1-001 would bind the chiral site in cryAB.
Molecular Docking Suggests That VP1-001, But Not
Its Enantiomer, Binds a Deep Groove in the Native
cryAB Dimer
In silico docking studies were performed to predict how VP1-
001 and ent-VP1-001 bind cryAB. There are multiple,
nonequivalent structures of the cryAB ACD solved by
crystallography and NMR.21,32–34 Most of the differences
among these structures occur at the dimer interface, where
an extended b-sheet that is either flat and coplanar or curved
and V-shaped exists between the two protomers. The b-sheets
that form the dimer interface were crystalized in three different
registers.33 This structural information suggests that the dimer
has conformational flexibility. Accordingly, we started with one
representative structure (PDB: 2WJ721) to create several
models by varying the angle of the two protomers relative to
one another. These motions influenced the size and shape of
the binding pocket for VP1-001.17 Six of these models were
considered, and the angle between protomers was increased
from 08 to 208 in 48-increments. Docking of VP1-001 and ent-
VP1-001 revealed that the 168 closed structure was the last in
the series to accommodate VP1-001. In the remaining four
models, including the 88 example (Fig. 2), VP1-001 fit well into
the known binding pocket. Specifically, the sterol rings made
contacts with hydrophobic side chains on either side of the
groove. By contrast, the terminal hydroxyl groups were
positioned to make hydrogen bonds with residues on either
end of the groove (Fig. 2B, green lines). Notably, when VP1-00
hydroxyls were positioned to interact with R120 residue, a key
residue mutated in some cases of hereditary cataracts, we
observed an additional potential hydrogen bond with the R116
residue. Next, we found that ent-VP1-001 did not fit well into
the groove due to misalignment of possible hydrogen bond
partners and steric clashes with hydrophobic residues in the
groove. Thus, even the best models of ent-VP1-001 showed
that much of the compound projected out of the groove. These
docking studies suggested that only VP1-001 would bind
cryAB.
VP1-001, But Not Its Enantiomer, Binds and
Stabilizes cryAB
To test our computational and structural predictions, we
measured binding of VP1-001 and ent-VP1-001 to cryAB in vitro
using two different methods. DSF was used to calculate an
apparent Tm for solutions of purified, recombinant cryAB
ACD.35,36 In this platform, binding of a ligand to cryAB ACD
was predicted to shift the apparent Tm to a higher tempera-
ture.37,38 Consistent with this prediction, we found that VP1-
001, but not ent-VP1-001, dose-dependently (Fig. 3A; n¼ 3, P
< 0.0001 2-way ANOVA 0 lM versus 100 lM VP1-001)
increased stability of cryAB ACD (Fig. 3A; n¼ 3, P < 0.0001 2-
way ANOVA 100 lM ent-VP1-001 versus 100 lM VP1-001).
Next, we used an orthogonal method, MST, to verify this
result using cryAB oligomers. MST relies on tracking the
movement of a fluorescently tagged protein through a thermal
gradient.39,40 We engineered a unique cysteine residue (E87C)
FIGURE 1. VP1-001 and ent-VP1-001 have the same physical properties but distinct shapes. (A) Chemical structures and physicochemical properties
of the oxysterol VP1-001 and its enantiomer ent-VP1-001. Total polar surface area is the sum of the surface contributions of polar atoms. Calculated
logP is a measure of hydrophilicity and is defined as the partition coefficient of a compound in mixtures of n-octanol and water. (B) Three-
dimensional comparison of the structures of VP1-001 and its enantiomer in different orientations, highlighting the distinct shapes. These structural
differences were predicted to hinder binding of ent-VP1-001 to cryAB by misaligning the key hydroxyl groups (red).
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into cryAB ACD and selectively labeled it with a cysteine-
reactive Alexa Fluor dye to generate AF488-cryAB(E87C) ACD.
Because cryAB protomers undergo subunit exchange, we
mixed AF488-cryAB(E87C) ACD into full-length oligomers to
reconstitute a fluorescently labeled protein sample for MST.
Binding affinity was calculated from a fit of the dose-responsive
MST signal change using the law of mass action.41 Consistent
with docking and DSF studies, we found that VP1-001 bound
cryAB 7-fold more strongly than ent-VP1-001, with VP1-001 KD
¼ 56 6 7 lM versus ent-VP1-001 KD¼ 370 6 30 lM (Fig. 3B, n
¼ 3). Importantly, the ent-VP1-001 binding curve did not
saturate at 250 lM, so the KD value for that compound is only
an estimate.
VP1-001, But Not ent-VP1-001, Partially Restores
Transparency in Cataract Mouse Models
The cryAB(R120G) mice harbor a mutation that causes lens
opacities to develop as early as 8 weeks at a frequency 3-fold
higher than that in WT mice.14 We previously found that
topical application of VP1-001 partially reverses cataract
formation in these mice even when they are more than 1 year
of age.17 Based on biophysical studies and the hypothesis that
binding to cryAB is important, we predicted that only VP1-001
would be active in this animal model. One eye of each animal
was treated topically with ent-VP1-001 or VP1-001 (1 mM in 8%
cyclodextrin), and the other eye was treated with vehicle
alone. Treatments were given three times per week for 2
FIGURE 3. VP1-001 binds to the ACD and full-length a-crystallin, but ent-VP1-001 does not. (A) Measured Tm of cryAB ACD (WT) calculated from
Boltzmann fits of DSF traces (n¼3). The shaded gray area represents three standard deviations from the DMSO control. ent-VP1-001 does not shift
the thermal stability of the ACD, whereas VP1-001 does. (B) Normalized binding (n¼3) to full-length cryAB (R120G) measured by MST. The shaded
gray region represents three standard deviations from the DMSO control. Calculated KD values: VP1-001¼ 56 6 7.0 lM; ent-VP1-001¼ 370 6 30
lM. Thus, VP1-001 binds tighter to cryAB than ent-VP1-001 does, consistent with the increased number of predicted contacts in the docking
studies. Note that the ent-VP1-001 curve does not fully saturate, so the calculated KD value is only approximate.
FIGURE 2. VP1-001 binds to the ACD, but ent-VP1-001 does not. (A) Electrostatic surface model of the ACD dimer in complex with docked VP1-001
(top) or ent-VP1-001 (bottom). Note the relatively poor ability of ent-VP1-001 to fit into the pocket. (B) Ribbon views of the ACD pocket with bound
VP1-001 (top) or ent-VP1-001 (bottom). Green lines (top) indicate predicted hydrogen bonds (distance 4 A˚ or less). The protein coordinates are
from the x-ray structure 2WJ7. However, the angle between protomers (shown in white and gray) was reduced by 88 by a rigid body movement (as
described in Methods).
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weeks. Lens transparency was measured by slit lamp biomi-
croscopy and graded using a previously published cataract
scoring system (see Methods). Mouse cohorts ranged in age
from 187 to 362 days and were age matched between
treatment groups (Fig. 4). In 9 of 13 cryAB(R120G) heterozy-
gous mice that received ent-VP1-001 treatment, there was
either no change or an increase in cataract lens grade relative
to vehicle controls. The remaining four mice exhibited
improvements not exceeding one grade (posttreatment lens
opacity grade, 2.6 6 0.50, P ¼ 0.22; Fig. 4A). Representative
slit lamp images are shown comparing ent-VP1-001 to the
vehicle-treated, contralateral eye (Fig. 4). By contrast, and in
agreement with previous work, the lenses of animals treated
with VP1-001 were significantly improved (lens opacity grade,
1.2 6 0.43, P < 0.0001, Fig. 4). Strikingly, the magnitude of the
improvement was at least two grades in 9 of 13 mice and at
least one grade in the other four mice. The VP1-001 lens
closely resembled a normal, 196-day-old, WT untreated lens
(Fig. 4).
Age-associated cataracts are far more prevalent in humans
than hereditary forms. Therefore, we compared the efficacy of
VP1-001 and ent-VP1-001 in aged WT C57BL/6J mice that had
spontaneously occurring, age-related cataracts. Using a similar
dosing scheme as described above, treatment of WT mice with
ent-VP1-001 did not significantly affect cataract grade (post-
treatment lens opacity grade, 2.6 6 1.1; n ¼ 4; P ¼ 0.61),
whereas VP1-001 did (lens opacity grade, 1.0 6 0.44; n¼ 10; P
¼ 0.0013; Fig. 5A). VP1-001 partially restored transparency in
both hereditary and age-associated murine models.
VP1-001, But Not ent-VP1-001, Increases the
Proportion of Water-Soluble Protein in
cryAB(R120G) Mouse Lenses
To determine the effects of these compounds on crystallin
aggregation and water solubility, we analyzed the RI and
average molecular weight of cryAB in mouse lenses treated
with ent-VP1-001 or VP1-001. RI measurements were conduct-
ed on water-soluble lens proteins and generated the expected
FIGURE 4. Treatment with VP1-001 significantly reduces cataract grade in cryAB(R120G) mutant mice, but ent-VP1-001 is inactive. (A) Cataract
grading for cryAB(R120G) heterozygous mice treated with either compound. The vehicle group represents combined contralateral eyes from both
treatment groups. (B) Age distribution of cryAB(R120G) heterozygous mice separated by treatment condition. Each point represents an individual
mouse lens. The mean is shown by a dotted line, and the error bars represent the standard errors from the means. (C–H) Representative slit lamp
images from a cryAB(R120G) heterozygous mouse showing the extent of lens opacity in vehicle-treated (C) and ent-VP1-001–treated eyes (D).
Representative slit lamp images from a cryAB(R120G) heterozygous mouse showing the extent of lens opacity in vehicle-treated (E) and VP1-001–
treated eyes (F). Representative slit lamp images from a cryAB(R120G) heterozygous mouse showing the extent of lens opacity in an untreated eye
(G). Representative slit lamp images from an untreated normal, WT mouse showing a clear lens (H).
Enantiomeric Study of VP1-001 Mechanism of Action IOVS j August 2019 j Vol. 60 j No. 10 j 3325
Downloaded from iovs.arvojournals.org on 08/06/2019
peaks for a-, b-, and c-crystallins.8 Here, as well as in previous
reports,17 VP1-001 appears to retain protein in the soluble
fraction (67% increase in protein solubility, n ¼ 7). Moreover,
the RI measurements showed larger peak areas for a-, b-, and c-
crystallins in the VP1-001–treated samples (Fig. 6A). VPI-001
increased the relative amount of total a-crystallin and b-
crystallins with less of an effect on c-crystallin. This result
suggests that VP1-001 increases the water-soluble proportion
of not only cryAB but also other lens crystallins, perhaps by
restoring chaperone function to cryAB in vivo. These results
are consistent with the reported association of a-crystallin with
b-crystallin and c-crystallin.5 In parallel sets of experiments, we
found that ent-VP1-001 did not improve the protein water-
soluble content compared with vehicle (Fig. 6C).
Among the lens crystallins, a-crystallins are the major
source of light scattering.8 Therefore, we used RALS measure-
ments to estimate the molecular weight of the a-crystallin
heterooligomer. Treatment with ent-VP1-001 did not change
the molecular weight distribution of a-crystallins compared
with that of vehicle-treated contralateral eyes, whereas VP1-
001 treatment showed a robust response (Table). The average
molecular weight of the oligomer decreased by 50% with VP1-
001 treatment (n ¼ 5), whereas treatment with ent-VP1-001
increased the average molecular weight by 8% (n ¼ 5).
Furthermore, the RALS peak shape was not altered by ent-
VP1-001 treatment (Fig. 6D), whereas VP1-001 shifted the peak
to the right (Fig. 6B). The decreased molecular weight of a-
crystallin in lenses treated with VP1-001 suggests that VP1-001
affects the self-association of aB-crystallin such that the protein
is less aggregated. These findings suggest that VP1-001
treatment may be beneficial to the protective functions of a-
crystallins.
The water-soluble supernatants from homogenized lenses
obtained from aged WT (C57BL/6J) mice were also tested by
GPC. There was a large difference in the RALS peak shape of
the VP1-001 and ent-VP1-001 groups (Fig. 5B). The vehicle-
treated samples had broad peaks consistent with aggregated
material, whereas treatment with VP1-001 eliminated a large
portion of the higher-molecular-weight a-crystallin oligomer
peak. The broad peak also shifted the retention volume by 3
mL with VP1-001 treatment (Fig. 5B). In contrast, ent-VP1-001
had no effect.
Effect of VP1-001 and ent-VP1-001 Treatment on
Lens Epithelial Cell-Cell Contacts and Lens Fiber
Cell Morphologies in cryAB(R120G) Mice
EM was performed 3 days after treatment ended to assess
epithelial and lens fiber architecture in treated cryAB(R120G)
mice. We investigated the effect of VP1-001 and ent-VP1-001
on newly formed lens epithelial and fiber cells during the
treatment period. Lens epithelial sections display the cells just
adjacent to the lens capsule in the equatorial region (Fig. 7).
Fiber cell sections show the cross-sectional view of cortical
fiber cells that have most recently differentiated in these adult
FIGURE 5. Treatment with VP1-001 significantly reduces cataract grade and refractive measures in aged WT C57BL/6J mice, but ent-VP1-001 is
inactive. (A, top) Cataract grading for aged WT C57BL/6J mice treated with either compound. Vehicle group represents contralateral eyes from both
treatment groups. (A, bottom) Age distribution of WT C57BL/6J mice separated by treatment condition. Each point represents an individual mouse
lens. The mean is shown by a dotted line, and the error bars represent the standard errors from the means. (B) Comparison of GPC RALS of water-
soluble fractions from homogenized lens tissues of VP1-001 or ent-VP1-001–treated and contralateral vehicle-treated eyes.
TABLE. Differences in Molecular Weight and Water-Soluble a-Crystallin
Concentration From cryAB(R120G) Heterozygous Mouse Lenses
Mouse
Lens
Treatment
Avg. Molecular
Weight
D Protein
Concentration
864-3 Vehicle 1270
ent-VP1-001 1238 0.14
983-4 Vehicle 1036
VP1-001 561 1.2
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mice. Both eyes (vehicle and compound) were imaged from
cryAB(R120G) heterozygous mice treated with VP1-001 (10
images/eye; n¼ 8 mice) or ent-VP1-001 (7–13 images /eye; n¼
6 mice). The average numbers of epithelial or fiber cell images
with morphologic damage were counted, and differences
between treated and untreated (vehicle) eyes were assessed by
t test.
The vehicle-treated lenses displayed disorganization (Fig. 7),
similar to that of sections previously imaged by immunofluo-
rescence microscopy.14 Large intercellular gaps in lens
epithelium were observed (red arrows). Disruption of contacts
between the lens capsule and epithelium were also observed
in vehicle-treated lenses (left red arrow in Fig. 7A2). In the
equatorial fiber cells, there was normal fiber cell elongation,
but cell packing was not uniform, and membranes appear
blebbed and irregular. The morphologies of lenses treated with
ent-VP1-001 were similar to those treated with vehicle with
disordered epithelial and fiber cell layers (Fig. 7; images
represent a majority, 75%, of sections). Conversely, VP1-001
had a striking effect on epithelial cell-cell contacts and fiber
cell packing, with the hexagonal architecture resembling
healthy tissue (Fig. 7, top; images represent a majority, 88%,
of sections). We measured a statistically significant difference
in morphologic damage in lens sections treated with VP1-001
versus vehicle (or enantiomer) (t test, P < 0.001).
Effect of VP1-001 and ent-VP1-001 on Cell-Cell
Contacts in Aged WT Mice
We also analyzed electron micrographs of lens sections from
aged WT mice to determine if they showed abnormal lens
morphologies that improved after treatment with VP1-001 (32
images/eye; n¼ 4 mice) or ent-VP1-001 (15 images/eye; n¼ 2
mice). The lens epithelium of vehicle-treated lenses from aged
WT mice exhibited disruption of the cell-cell interface near the
capsule (Fig. 8A) similar to cryAB(R120G) heterozygous mice
(Fig. 7, left). These abnormalities were eliminated in lenses
treated with VP1-001, but not ent-VP1-001. In these experi-
ments, we noted that fiber cell morphology in aged mice was
less disorganized than in the mutant model; nevertheless, we
observed nonuniform cell sizes, irregular packing, and limited
membrane blebbing. The fiber cells of aged mouse lenses
showed slight improvement with ent-VP1-001 treatment, with
the appearance of the expected hexagonal shape in some cells.
The improvement in morphology was more pronounced with
VP1-001 treatment (Fig. 8B, top right).
To better understand the prominent gaps at the capsular
interface in the aged mice, we captured higher magnification
images of cell-cell contact surfaces in the epithelium (Fig. 9). In
the vehicle-treated lenses, gaps were interspersed among
normal cell-cell boundaries, suggesting local areas of weakened
interactions. Notably, these gaps were absent from VP1-001–
FIGURE 6. Treatment with VP1-001 significantly increases protein solubility in lenses of cryAB(R120G) mutant mice, but ent-VP1-001 is inactive.
Homogenized tissue from cryAB(R120G) heterozygous mice treated with vehicle, VP1-001 (A), or ent-VP1-001 (C) were separated by GPC and
measured by RI to reveal peaks for a–, b-, and c-crystallins. Alternatively, samples were measured for RALS to study the molecular mass of soluble a-
crystallin (B, D). Treatment with VP1-001 (A), but not ent-VP1-001 (C), increased the amount of soluble lens protein compared with vehicle. In all
chromatography traces, the treatments were compared with vehicles taken from the contralateral eye of the same mouse.
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treated lenses. To our knowledge, these are the first observa-
tions of large gaps at the cell-cell interfaces of epithelial cells in
cataract models. Previous immunofluorescence studies of
cataract lenses in 12-week-old mice did not report these gaps.14
However, we attribute this difference to the more advanced age
of the mice in the current study (aged 31–35 weeks).
DISCUSSION
Stable interactions between small heat shock proteins and
their substrates do not necessarily prevent protein aggrega-
tion.42 However, some small heat shock proteins do hinder
aggregation through transient interactions.42 Thus, binding
and aggregation are two separately controlled processes. In a
cellular complex, both transient and stable interactions are
likely to contribute to these processes. CryAB activity limits
aggregation by maintaining protein solubility in the lens,
preventing cataract formation. In this work, we probed how a
small-molecule ligand for cryAB, VP1-001, might maintain its
function. A classical and rigorous approach is to characterize
the activity of the enantiomer because interactions with chiral
proteins will only occur with one enantiomer. For example,
FIGURE 7. VP1-001, but not ent-VP1-001, improves lens morphology in cryAB(R120G)-mutant mice. Electron micrographs of lens epithelium and
lens fiber cell sections from four mice are grouped horizontally (for example, images A1, B1, C1, and D1 are from one mouse). Scale bars: 2 lm,
white. Red arrows indicate vacuoles, cyan arrows indicate an abnormal nuclear shape, yellow arrows indicate irregular cell size, and white arrows
indicate abnormal cell protrusions. (Left) Lens epithelial sections from treated and untreated eyes of cryAB(R120G) heterozygous mice. For each
treatment condition, two replicate mice are displayed. (Right) Lens fiber sections from the same four mice. The images are representative of a
majority of the sections from mice. In contrast to VP1-001, the enantiomer did not reverse morphologic changes in cryAB(R120G) heterozygous
mice. (Bottom panel) Low-magnification image of a lens treated with VP1-001. The equatorial region in which the EM images were taken is
enclosed by a box. Scale bar: 0.5 mm, black.
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direct interaction of the anticancer compound, YK-4-279,
with its target was confirmed using its enantiomer.43 This
approach is powerful, because the enantiomers of active
compounds have identical physical properties. Thus, the
enantiomer can be used to rule out alternative models, such
as chemical chaperone activity or interactions with mem-
branes. By comparing the activities of VP1-001 to ent-VP1-
001, we aimed to address several important mechanistic
questions.
We found that VP1-001 was predicted to bind into a deep
groove in the cryAB ACD dimer. In this bound state, key
hydrogen bond contacts were predicted at both extremes of
the groove at the dimer interface (see Fig. 2). However, ent-
VP1-001 did not make these same contacts and was predicted
to have weaker affinity. Indeed, these predictions were
experimentally confirmed with two biophysical methods,
DSF and MST. VP1-001 bound better to cryAB than did ent-
VP1-001. Thus, we were able to use these compounds to
rigorously probe whether direct binding to cryAB was required
to improve lens transparency and protein solubility in mouse
models. More explicitly, if we found that ent-VP1-001 was
bioactive in vivo, then we would conclude that alternative,
nonstereospecific mechanisms, such as membrane interac-
tions, may contribute to the activity of VP1-001. In this way, the
results would have a profound impact on the future
development of anticataract compounds. If binding to cryAB
is important (e.g., VP1-001 is active, but ent-VP1-001 is
inactive), then further optimization would likely require
increasing affinity for cryAB. In contrast, if alternative
mechanisms existed (e.g., both compounds were active), then
one would envision ways of improving activity by promoting
lipophilicity and membrane binding. As discussed in greater
detail below, we found that VP1-001, but not ent-VP1-001, was
active in a range of biological cataract assays. Thus, one major
conclusion of these studies is that direct binding to cryAB is
required for the observed biological activity of VP1-001.
Previous studies demonstrated that expression of WT a-
crystallin protects the lens epithelium from a variety of stress
conditions and mutations.44 Our in vivo studies in mutant mice
with cataracts revealed that VP1-001, but not ent-VP1-001,
partially corrected lens transparency, as assessed by the
cataract grading scale and decreased average molecular weight
of cryAB oligomers. We also tested VP1-001 and ent-VP1-001 in
WT aged mice, which is critical because cataracts in old mice
are expected to arise from a more heterogeneous set of
circumstances. Indeed, mass spectrometry studies have shown
that aged lens proteins harbor many posttranslational modifi-
cations that accumulate over time, including oxidation,45
glycation,46 deamidation,47 racemization, and isomerization.48
The ability of VP1-001 to lower the cataract grade and the
appearance of nearly normal lens morphology in the newly
FIGURE 8. VP1-001, but not ent-VP1-001, improves lens morphology in
aged WT C57BL/6J mice. Electron micrographs of lens epithelium and
lens fiber cell sections from three mice. Scale bars: 2 lm, white. Mouse
3 was imaged at a slightly lower magnification. (A) Lens epithelial
sections from contralateral treated and untreated eyes of two WT
C57BL/6J mice. Red arrows indicate the gaps between adjacent cells.
(B) Lens fiber sections from two mice. Yellow arrows indicate irregular
cell size. White arrow indicates a vacuole. The appearance of normal
cell-cell associations in the lens epithelium of VP1-001–treated mice
suggests that VP1-001 improves morphologic changes associated with
aging of the lens epithelium.
FIGURE 9. VP1-001 protects cell-cell contacts in the lens epithelia of
aged WT C57BL/6J mice. Electron micrographs of lens epithelium
sections from contralateral treated and untreated eyes of WT mice.
White arrows indicate typical healthy cell-cell contacts, whereas red
arrows indicate areas of weak adhesion. Scale bars: 0.5 lm, black.
(Left panels) Lens epithelial cell sections from two mice treated with
vehicle only. (Right panels) Lens epithelial cell sections from the
contralateral eyes of the same mice treated with 1 mM VP1-001.
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synthesized epithelial and fiber cells in the aged mice are
particularly interesting. Despite a heterogeneous collection of
molecular defects, VP1-001 was able to compensate for
damage to cryAB in the lens epithelial and fiber cells of the
equatorial region of the lens and improve lens epithelial cell
morphology (see Figs. 7–9) and fiber cell packing (see Figs. 7,
8). Adult mouse lenses add approximately 100 to 200 lens
epithelial cells per day. No cell death is observed in the adult
mouse lens epithelium, indicating that 100 to 200 lens
epithelial cells differentiate per day into fiber cells.49 Our data
suggest that the newly differentiated lens fiber cells, which
emerged during the course of VP1-001 treatment, adopted a
normal structure and are overlaid on the deformed cells. The
appearance of normal cell-cell contacts in the lens epithelium
of VP1-001–treated mice suggests that binding of VP1-001 to
cryAB improves the morphology of the lens epithelium.
Our EM studies suggested that normal cell-cell interactions
in the lens epithelium may contribute to the effects of VP1-001.
In addition, we observed concurrent enhancement in the
soluble fraction of b- and c-crystallin (Figs. 5A, 6B), which does
not directly bind to VP1-001.17 Taken together, these observa-
tions suggest that binding of VP1-001 does not disrupt cryAB
normal function. Indeed, we speculate that compound-bound
cryAB may still function as a chaperone and that this activity
may contribute to the potency of VP1-001 in these models.
Future studies using in vitro chaperone assays would corrob-
orate this speculation.
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